Neurogene
NGNE • NASDAQ
Neurogene is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Rachel L. McMinn, with a market cap of $316.9M.
CEORachel L. McMinn
Next Earnings
Upcoming earnings announcement for Neurogene
Date
Friday, May 8, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.32
Earnings History
Past 8 earnings reports for Neurogene
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | Q4 2025 | -$1.13Est: -$1.21 | +6.6% | - | — |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.99Est: -$1.16 | +14.7% | - | — | 10-Q |
| Aug 11, 2025 | Q2 2025 | -$1.05Est: -$1.09 | +3.7% | - | — | 10-Q |
| May 9, 2025 | Q1 2025 | -$1.08Est: -$0.92 | -17.4% | - | — | 10-Q |
| Mar 24, 2025 | Q4 2024 | -$1.00 | — | - | — | 10-K |
| Nov 18, 2024 | Q3 2024 | -$1.19Est: -$1.22 | +2.5% | - | — | 10-Q |
| Aug 9, 2024 | Q2 2024 | -$1.09Est: -$1.05 | -3.8% | $925.0K | — | 10-Q |
| May 10, 2024 | Q1 2024 | -$1.00Est: -$1.13 | +11.5% | - | — | 10-Q |